首页> 美国卫生研究院文献>Pharmacogenomics and Personalized Medicine >Clinical application of high throughput molecular screening techniques for pharmacogenomics
【2h】

Clinical application of high throughput molecular screening techniques for pharmacogenomics

机译:高通量分子筛查技术在药物基因组学中的临床应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Genetic analysis is one of the fastest-growing areas of clinical diagnostics. Fortunately, as our knowledge of clinically relevant genetic variants rapidly expands, so does our ability to detect these variants in patient samples. Increasing demand for genetic information may necessitate the use of high throughput diagnostic methods as part of clinically validated testing. Here we provide a general overview of our current and near-future abilities to perform large-scale genetic testing in the clinical laboratory. First we review in detail molecular methods used for high throughput mutation detection, including techniques able to monitor thousands of genetic variants for a single patient or to genotype a single genetic variant for thousands of patients simultaneously. These methods are analyzed in the context of pharmacogenomic testing in the clinical laboratories, with a focus on tests that are currently validated as well as those that hold strong promise for widespread clinical application in the near future. We further discuss the unique economic and clinical challenges posed by pharmacogenomic markers. Our ability to detect genetic variants frequently outstrips our ability to accurately interpret them in a clinical context, carrying implications both for test development and introduction into patient management algorithms. These complexities must be taken into account prior to the introduction of any pharmacogenomic biomarker into routine clinical testing.
机译:遗传分析是临床诊断领域发展最快的领域之一。幸运的是,随着我们对临床相关遗传变异的了解迅速扩展,我们检测患者样本中这些变异的能力也在不断提高。对遗传信息的需求不断增长,可能需要使用高通量诊断方​​法作为经过临床验证的测试的一部分。在这里,我们概述了我们目前和将来在临床实验室中进行大规模基因检测的能力。首先,我们详细审查用于高通量突变检测的分子方法,包括能够监测单个患者的数千个遗传变异或同时对数千个患者进行单个遗传变异的基因分型的技术。这些方法是在临床实验室的药物基因组测试的背景下进行分析的,重点是当前已通过验证的测试以及在不久的将来具有广泛临床应用前景的测试。我们进一步讨论了药物基因组标记物所带来的独特的经济和临床挑战。我们检测遗传变异的能力经常超过我们在临床环境中准确解释遗传变异的能力,对测试开发和引入患者管理算法都具有影响。在将任何药物基因组生物标记物引入常规临床测试之前,必须考虑这些复杂性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号